We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
To bridge the gulf between the promise of biosimilars on drug pricing and the reality, payors should incentivize biosimilar utilization, a new report states. Read More
The UK’s National Institute for Health and Care Excellence has recommended reimbursement for PTC Therapeutics’ Translarna for the treatment of Duchenne muscular dystrophy. Read More
It took Pfizer and Allergan less than 48 hours to nix their plan to build one of the world’s largest drugmakers, placing the blame squarely on the U.S. Treasury Department. Read More
Federal efforts to protect the drug supply chain continue to bear fruit, with the FDA’s Office of Criminal Investigations announcing criminal charges for another counterfeit operation. Read More
UK regulators have fined Pfizer $14,000 for failing to explain a questionable claim meant to justify price increases on the generic seizure medication Epanutin. Read More
It took a few days and a threatened contempt of Congress citation, but Valeant Pharmaceuticals International’s CEO J. Michael Pearson has agreed to meet with Senate officials investigating rising prescription drug prices. Read More